HCWBHCW Biologics
About HCW Biologics
HCW Biologics (NASDAQ:HCWB) is a clinical-stage company developing immunotherapies to combat chronic, low-grade inflammation, a hallmark of aging and many diseases. Their focus is on disrupting this inflammatory process to improve healthspan, essentially the length of healthy life. They're currently in the development phase of novel immunotherapeutic drugs and haven't launched any commercial products yet. HCW Biologics is a small-cap company with a market capitalization around $41 million.
What is HCWB known for?
Snapshot
Public US
Ownership
2018
Year founded
45
Employees
Miramar, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Miramar, US
Produtos e/ou serviços de HCW Biologics
- Immunotherapy Research & Development: HCW Biologics researches and develops novel immunotherapy drugs targeting chronic, low-grade inflammation.
- Pre-Clinical and Clinical Trials: They conduct pre-clinical studies in labs and potentially clinical trials to test the safety and efficacy of their drug candidates.
- Collaboration with Research Institutions: HCW Biologics might collaborate with other research institutions to advance their discoveries.
- Data Analysis & Reporting: They analyze data from studies and trials, reporting findings to regulators and the scientific community.
- Investor Relations & Communication: HCW Biologics communicates with investors regarding their progress and developments.
- Intellectual Property Management: The company likely manages patents and other intellectual property related to their discoveries.
equipe executiva do HCW Biologics
- Dr. Hing C. Wong Ph.D.Founder, CEO, Director & Secretary
- Ms. Rebecca Byam CPA, M.B.A.Chief Financial Officer
- Dr. Peter Rhode Ph.D.Chief Scientific Officer & VP of Clinical Operations
- Ms. Nicole Valdivieso Esq.Vice President of Legal Affairs
- Mr. Lee D. FlowersSenior Vice President of Business Development